Skip To Main Content
Robert Barrie on Muck Rack

Robert Barrie

Verified
London
As seen in: Clinical Trials Arena, Medical Device Network, MSN, Yahoo Finance, New Scientist, Yahoo, EIN News, NewsBreak, Pharmaceutical-Technology.com, Yahoo Finanzas, Just-Drinks, Just-Food and
Healthcare reporter at GlobalData
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Robert

Contact Robert, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

No more Nordisk: Novo’s latest trim is in its name Original

|
By Robert Barrie Verified
| Pharmaceutical-Technology.com Verified
Joining a minimalistic wave in pharma marketing, Novo said the change increases memorability and relevance. While Novo Nordisk will remain its legal name, the change means Novo will be its front-facing identifier alongside its trusted Apis bull. Credit: Novo. When Mike Doustdar joined Novo Nordisk as CEO, he emphasised corporate evolution. Now, a year later, he has delivered a major rebranding as the drugmaker simplifies both its name and image.
Open in Who Shared View Duplicates (2) Issue with article?

Pressure intensifies on Novartis as bolt-on deal strategy faces major test

|
By Robert Barrie Verified
| Pharmaceutical-Technology.com Verified
As part of GlobalData's extensive network of websites, this site is dedicated to protecting your privacy. We may store and access personal data such as cookies, device identifiers or other similar technologies on your device and process such data to enhance site navigation, personalize ads and content when you visit our sites, measure ad and content performance, gain audience insights, analyze our site traffic as well as develop and improve our products and services.
Open in Who Shared Issue with article?

Pressure intensifies on Novartis as bolt-on deal strategy faces major test

|
By Robert Barrie Verified
| Clinical Trials Arena Verified
Share prices tumbled last week after a key asset from Novartis' $12bn Avidity deal fumbled in a Phase III trial.
Open in Who Shared Issue with article?
See all 2,844 articles